Facebook
Twitter
LinkedIn
Forward
Symposia 1 - The WHO System for Reporting Lung Cytopathology: The Rationale, Structure Categories and Application
The WHO System for Reporting Lung Cytopathology has been developed and a book published by an expert editorial board of cytopathologists brought together by the WHO publisher IARC in a joint program with the International Academy of Cytology over the last eighteen months. The Reporting System is based on 5 well defined categories each of which has a risk of malignancy. The aim is to standardize the approach to reporting lung cytopathology including sputa, bronchial washes, bronchial brushes and fine needle aspiration biopsies. The Reporting System is centered on defined lesions and tumors that directly correlate with the WHO Classification of Tumors Thoracic ‘blue book’ and presents established key cytopathological diagnostic features for each lesion and a differential diagnosis based on the cytopathology and the use of ancillary testing to assist the diagnosis. The ultimate aim is to assist communication with clinicians and improve patient care. This symposium presents didactic lectures introducing the reporting system and providing information on the rationale, structure, reporting categories, and application of the system in routine reporting.
Target Audience
This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.
Learning Objectives
- Understand the rationale, structure, categories and application of the new WHO System for Reporting Lung Cytopathology
- Understand how to apply the new system to their routine reporting in lung cytopathology
- Become aware that the consensus key diagnostic cytopathological features. the differential diagnosis of the cytopathology features and the ancillary testing are the core elements of the book
Presenter(s):
Lukas Bubendorf, MD, MIAC
Ashish Chandra, MD, FRCPath, DipRCPath (Cytol)
Andrew Field, MBBS (Hons), FRCPA, FIAC, DipCyto(RCPA)
Lester Layfield, MD
Martha Pitman, MD
Fernando C. Schmitt, MD, PhD, FIAC
Maureen F. Zakowski, MD, JD
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.
The following individuals have reported financial relationships:
Michael Berry, SCT(ASCP)MBCM: Stockholder-Hologic
Lukas Bubendorf, MD, MIAC: Advisory Board - Astra Zeneca, Bayer, Eli Lilly, BMS, Takeda; Research Support - Sanofi, Systems Oncology, Thermo Fisher; Speaker's Fee - Thermo Fisher; Consultant – Systems Oncology, Janssen
Oscar Lin, MD, PhD: Consultant – Hologic and Jansen
Liron Pantanowitz, MD: Consultant – Hamamatsu, Advisory Board for Ibex
Martha B. Pitman, MD, FIAC: Consultant – Adenocyte, LLC
Donna K. Russell, MEd, CT(ASCP), HT(ASCP): Advisory Board – Hologic Scientific
Christopher J. VandenBussche, MD, PhD: Ad hoc advisory board panel and Consultant – Roche
Paul VanderLaan, MD, PhD: Consultant – Gala Therapeutics
The following individuals have reported no relevant financial relationships:
Susan A. Alperstein, MS, CT(ASCP), Kristen A. Atkins, MD, Zubair, Baloch, MD, PhD, Guliz A. Barkan, MD, Christine N. Booth, MD, Leigh Ann Cahill, BS, CT(ASCP)CMIAC, Barbara A. Centeno, MD, Ashish Chandra, MD, FRCPath, DipRCPath (Cytol), Deborah J. Chute, MD, Amy C. Clayton, MD, Jacqueline M. Cuda, BS, SCT(ASCP), Fang Fan, MD, PhD, Andrew Field, MB BS(Hons) FRCPA FIAC DipCytopath(RCPA), Kara L. Hansing, MEd, SCT(ASCP)CM, Lester Layfield, MD, Aparna M Mahajan MD, Sara E. Monaco, MD, Michiya Nishino MD, PhD, N. Paul Ohori MD, Lynnette S. Pineault, MBA, SCT(ASCP), Sinchita Roy-Chowdhuri, MD, PhD, Fernando C. Schmitt, MD, PhD, FIAC, Momin T. Siddiqui, MD, FIAC, Z. Laura Tabatabai, MD, Sana O. Tabbara, MD, Michael J. Thrall, MD, Dena M. Tonkovich, BS, CT(ASCP), Dawn L. Underwood, MS, CT(ASCP), Vivian L. Weiss, MD, PhD, Teresa Wood, MPH, BA, CT(ASCP), Maureen F. Zakowski, MD, JD, Lisa Zhang, MD
The ASC staff associated with the development of content for this activity reported no relevant financial relationships.
Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Board of Pathology Maintenance of Certification (CC)
This product can help fulfill the CME requirements mandated by the American Board of Pathology Continuing Certification (CC) process. Earn up to 2.0 Credit Hours.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the States of Florida and California. The credit on each link is good for three years from the live presentation date.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 California Credits
- 2.00 CMLE
- 2.00 Florida Credits
- 2.00 Participant